2 results about "Tube formation" patented technology

This application provides a polypeptide whose amino acid sequence includes the amino acid sequence shown in SEQ ID NO.1. The amino acid sequence of SEQ ID NO.1 is GPPVSE. This application also provides the application of the above-mentioned polypeptide in medical aesthetics and tissue repair products that promote cell proliferation and migration and endothelial tube formation. This application also provides a tissue repair product comprising the above-mentioned polypeptide. This application conducts research and development on polypeptide components in placental polypeptide extracts, and identifies and screens a monomeric polypeptide component that promotes tissue repair from placental polypeptide extracts.

This invention discloses the application of GLPG0187 in combination with propranolol in the preparation of drugs for the treatment or inhibition of hemangiomas. GLPG0187 is an integrin β1 inhibitor, and propranolol is a β-receptor blocker. This invention was validated through CCK8 assays, scratch assays, and tube formation assays. The results showed that, compared with propranolol monotherapy, GLPG0187 (4 nM) combined with propranolol (20-30 μM) could further inhibit the proliferation, migration, and tube formation ability of human hemangioma endothelial cells, demonstrating superior efficacy compared to propranolol monotherapy. This invention addresses the issue that approximately 2.1% of patients treated with propranolol monotherapy for infantile hemangiomas experience side effects such as sleep disturbances, bronchospasm, and hypoglycemia, providing a new combination therapy regimen and offering a new drug option for reducing the clinical dosage of propranolol and minimizing the risk of side effects. This invention identifies a new target for the treatment of hemangiomas, providing new possibilities for hemangioma treatment.